Skip to content

Arrowhead Research ARWR Other current assets

Other current assets at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Royalty Pharma logo
Royalty PharmaRPRX
Revvity logo
RevvityRVTY
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Amgen logo
AmgenAMGN
Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsCurrent.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's other current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's other current assets?
Arrowhead Research (ARWR) reported other current assets of $18.25M in Q1 2026.
How has Arrowhead Research's other current assets changed year-over-year?
Arrowhead Research's other current assets increased by 56.3% year-over-year, from $11.68M to $18.25M.
What is the long-term trend for Arrowhead Research's other current assets?
Over 5 years (2020 to 2025), Arrowhead Research's other current assets has grown at a 50.0% compound annual growth rate (CAGR), from $1.78M to $13.52M.